As drugmakers attempt to move up the value chain to manufacture sophisticated new medicines in China, General Electric Co wants to sell them factories: right off the shelf.
GE shipped its first prefabricated biopharmaceutical factory from Germany to China in September. The building made its way to a biotechnology zone in the central Chinese city of Wuhan bundled in 62 containers — traveling along the Rhine and Yangtze rivers and going by sea in between. In China, the factory was assembled and built in 11 days.
The idea is to help pharma companies gain a head start in China as they navigate a lengthy approval process for new drugs.
GE says the prefabricated factories help them cut costs and timing by about half when compared with traditional facilities. As healthcare costs soar, there is rising demand in China for cheaper access to more complex drugs called biologics and their more affordable generic cousins, called biosimilars.
CONSULTATION
Because these medicines usually contain live ingredients, the manufacturing process is also more complex. GE’s factories were developed after consultation with Chinese Food and Drug Administration officials, and that could help during the audit process, said Olivier Loeillot, GE Healthcare Life Sciences’ Asia general manager.
“It’s one single manufacturing concept that we can replicate around the world,” Loeillot said.
BLOCKBUSTER DRUGS
“As the pharmaceutical industry goes from big-volume blockbuster drugs to tailored, smaller-scale drug manufacturing we want to meet that demand,” Loeillot added.
China is the first country in which the GE prefabricated factories are being built and the company hopes to eventually take them around the world. It has seen interest in countries ranging from Turkey to Brazil, Loeillot said.
In other industries, prefabricated buildings have been used to reduce the time to market: For example, some McDonald’s restaurants have been prefabricated.
The GE factories, called KUBio, could also help the Connecticut-based company build on its presence in the biopharmaceutical supply chain.
DOUBLE-DIGIT GROWTH
GE Healthcare says that 90 percent of global US FDA-approved biologic medicines are made using its technology, and its life sciences business unit has been logging double-digit percentage revenue growth.
That demand could accelerate further as the patents on more drugs like AbbVie Inc’s Humira and Roche Holding AG’s Avastin expire in the coming years and companies around the world begin to make cheaper copies of such treatments.
Building a traditional plant can typically cost upwards of US$200 million and costs are sometimes well in excess of US$500 million, Loeillot said.
SAVING COSTS
Depending on the factory design and the drug being made, an equivalent KUBio from GE could reduce costs by as much as 45 percent, the company estimates. It is cheaper partly because it uses disposable equipment that saves days of cleaning and steaming — instead of stainless steel components.
The prefabricated factories include “clean rooms” where the environment is controlled for dust and other particles, and also piping, heating and ventilation. Even the toilets are prefabricated. So, for workers in China, assembling the plant would be much like working with Lego toy blocks.
MANUFACTURING
As the first factory was being built in Stuttgart, Germany, the buyer, a start-up company called JHL Biotech Inc was preparing the ground and infrastructure in China.
JHL, backed by Silicon Valley venture capital heavyweights Kleiner Perkins Caufield & Byers and Sequoia Capital, plans to manufacture biopharmaceuticals in China, JHL chief executive officer Racho Jordanov said.
Manufacturing costs in China are cheaper, but JHL aims to meet European and US standards.
The company is to file its first application next month in Europe to begin clinical trials, and is to follow with applications in China, said Jordanov, a 20-year veteran of the US biotech company Genentech. GE says its second order is coming from a big pharma company that is looking to broaden its production in China.
“If I was building the same thing in San Francisco, I would totally build it myself, but with this, I’m not going to take any chances,” Jordanov said of the pre-made factories.
“With this option, even if an inspector was blindfolded and put on airplane — if they walk into our plants they wouldn’t be able to tell if she was in Basel, Switzerland or Wuhan, China,” he said.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Sales in the retail, and food and beverage sectors last month continued to rise, increasing 0.7 percent and 13.6 percent respectively from a year earlier, setting record highs for the month of March, the Ministry of Economic Affairs said yesterday. Sales in the wholesale sector also grew last month by 4.6 annually, mainly due to the business opportunities for emerging applications related to artificial intelligence (AI) and high-performance computing technologies, the ministry said in a report. The ministry forecast that retail, and food and beverage sales this month would retain their growth momentum as the former would benefit from Tomb Sweeping Day